PL3334422T3 - Zastosowanie kwasu kannabidiolowego w leczeniu padaczki - Google Patents

Zastosowanie kwasu kannabidiolowego w leczeniu padaczki

Info

Publication number
PL3334422T3
PL3334422T3 PL16747593T PL16747593T PL3334422T3 PL 3334422 T3 PL3334422 T3 PL 3334422T3 PL 16747593 T PL16747593 T PL 16747593T PL 16747593 T PL16747593 T PL 16747593T PL 3334422 T3 PL3334422 T3 PL 3334422T3
Authority
PL
Poland
Prior art keywords
epilepsy
treatment
cannabidiolic acid
cannabidiolic
acid
Prior art date
Application number
PL16747593T
Other languages
English (en)
Inventor
Colin Stott
Nicholas Jones
Robin Williams
Benjamin Whalley
Original Assignee
GW Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Limited filed Critical GW Research Limited
Publication of PL3334422T3 publication Critical patent/PL3334422T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16747593T 2015-08-10 2016-07-29 Zastosowanie kwasu kannabidiolowego w leczeniu padaczki PL3334422T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514079.1A GB2541191A (en) 2015-08-10 2015-08-10 Use of cannabinoids in the treatment of epilepsy
PCT/GB2016/052340 WO2017025712A1 (en) 2015-08-10 2016-07-29 Use of cannabinoids in the treatment of epilepsy
EP16747593.8A EP3334422B1 (en) 2015-08-10 2016-07-29 Use of cannabidiolic acid in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
PL3334422T3 true PL3334422T3 (pl) 2020-12-28

Family

ID=54200465

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16747593T PL3334422T3 (pl) 2015-08-10 2016-07-29 Zastosowanie kwasu kannabidiolowego w leczeniu padaczki

Country Status (19)

Country Link
US (2) US11147783B2 (pl)
EP (2) EP3334422B1 (pl)
JP (2) JP6949822B2 (pl)
AU (1) AU2016305545B2 (pl)
CA (1) CA2992802C (pl)
CY (1) CY1123351T1 (pl)
DK (1) DK3334422T3 (pl)
ES (1) ES2820333T3 (pl)
GB (1) GB2541191A (pl)
HR (1) HRP20201506T1 (pl)
HU (1) HUE051476T2 (pl)
LT (1) LT3334422T (pl)
MX (2) MX379255B (pl)
PL (1) PL3334422T3 (pl)
PT (1) PT3334422T (pl)
RS (1) RS60852B1 (pl)
SI (1) SI3334422T1 (pl)
SM (1) SMT202000514T1 (pl)
WO (1) WO2017025712A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
BR112020004947A2 (pt) * 2017-09-19 2020-09-15 Zynerba Pharmaceuticals, Inc. canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CN112969452A (zh) * 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2020223510A1 (en) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Cannabinoid compositions and methods of using
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
WO2021037343A1 (en) 2019-08-27 2021-03-04 Herbolea Biotech S.R.L. Cannabinoid concentrate and isolate, method of obtaining the same and use thereof
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US20220304943A1 (en) * 2019-10-28 2022-09-29 Canopy Growth Corporation Flowable cannabinoid compositions having high effective concentrations
EP4054547A4 (en) * 2019-11-08 2024-03-27 Portland Technology Holdings LLC Hemp extract and methods of use thereof
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US20230201157A1 (en) * 2020-05-24 2023-06-29 Asana Bio Group Ltd. Compositions of cannabinoids and methods of using same
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
AR123432A1 (es) 2020-09-04 2022-11-30 Herbolea Biotech S R L Concentrado de cannabinoides libre de thc, método de obtención del mismo y su uso
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
EP4228611A4 (en) * 2020-10-17 2024-11-06 Mingowood Pharmacal, LLC FORMULATION AND NON-COVALENT STABILIZATION OF OLIVETOLIC ACID DERIVATIVES
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
JP2024536075A (ja) * 2021-10-11 2024-10-04 ニューロテック インターナショナル リミテッド 神経障害を処置するための組成物および方法
WO2023060302A1 (en) * 2021-10-11 2023-04-20 Neurotech International Ltd Compositions and methods for treating neurological disorders with combination products
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
US11551799B1 (en) * 2022-04-05 2023-01-10 Green Sky Creations LLC Multi-stage release cannabinoid compositions
US12020794B2 (en) 2022-03-17 2024-06-25 Green Sky Creations LLC Methods and systems for dispensing opioids according to pain-modulating regimen
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids
GB2629099A (en) * 2022-09-12 2024-10-16 Greenway Herbal Products Llc Cannabinoid and omega fatty acid compositions and methods of using
EP4577197A1 (en) * 2022-10-06 2025-07-02 Neurotech International Ltd Methods for treating paediatric neurological disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
US20250236581A1 (en) 2024-01-23 2025-07-24 Manoira Corporation Cannabidiolic acid cocrystals

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
EP1482917B1 (en) 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
SI1542657T1 (sl) 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
DK2311475T3 (en) 2002-08-14 2016-09-19 Gw Pharma Ltd Extraction of pharmaceutically active cannabinoids FROM PLANT MATERIALS
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
US20040110828A1 (en) 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US20080188461A1 (en) 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
CN101040855A (zh) 2007-04-12 2007-09-26 杨喜鸿 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
EP2023121A1 (en) 2007-07-06 2009-02-11 Bp Oil International Limited Optical cell
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CA2698752A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
LT2280687T (lt) 2008-03-26 2019-08-26 Stichting Sanammad Kramtomosios gumos kompozicijos, apimančios kanabinoidus
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
BRPI1014139A2 (pt) 2009-06-29 2016-04-26 Bender Analytical Holding Bv sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
PE20131096A1 (es) 2010-08-04 2013-10-10 Gruenenthal Chemie Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico
WO2012033478A1 (en) 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
CA2737447A1 (en) * 2011-04-27 2012-10-27 Antony Paul Hornby Hayley's comet
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
US9095554B2 (en) 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US9259449B2 (en) 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US20160000843A1 (en) * 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
CA2859934A1 (en) * 2014-09-22 2016-03-22 A. Paul Hornby Hayley's comet ii
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
WO2016084075A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016147186A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US20180185324A1 (en) 2015-06-11 2018-07-05 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (mm)
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Also Published As

Publication number Publication date
SI3334422T1 (sl) 2020-11-30
US20180228751A1 (en) 2018-08-16
JP7303267B2 (ja) 2023-07-04
MX379255B (es) 2025-03-11
DK3334422T3 (da) 2020-09-28
EP3769755A1 (en) 2021-01-27
JP2021191797A (ja) 2021-12-16
HUE051476T2 (hu) 2021-03-01
AU2016305545B2 (en) 2021-12-09
US20220062211A1 (en) 2022-03-03
EP3334422A1 (en) 2018-06-20
EP3334422B1 (en) 2020-07-01
WO2017025712A1 (en) 2017-02-16
MX2018001472A (es) 2018-04-24
CY1123351T1 (el) 2021-12-31
HRP20201506T1 (hr) 2021-02-05
CA2992802C (en) 2023-09-19
GB2541191A (en) 2017-02-15
SMT202000514T1 (it) 2020-11-10
US11147783B2 (en) 2021-10-19
JP2018527341A (ja) 2018-09-20
CA2992802A1 (en) 2017-02-16
GB201514079D0 (en) 2015-09-23
JP6949822B2 (ja) 2021-10-13
MX2021000814A (es) 2021-03-25
AU2016305545A1 (en) 2018-02-08
LT3334422T (lt) 2020-11-25
EP3769755B1 (en) 2023-05-24
RS60852B1 (sr) 2020-10-30
US11684598B2 (en) 2023-06-27
ES2820333T3 (es) 2021-04-20
PT3334422T (pt) 2020-09-29

Similar Documents

Publication Publication Date Title
SI3334422T1 (sl) Uporaba kanabidiolne kisline pri zdravljenju epilepsije
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201510664D0 (en) Use of cannabinoids in the treatment of epilepsy
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB201418171D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418170D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418166D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB201418169D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
IL254116B (en) Treatment of pancreatitis
IL253803A0 (en) A preparation for the treatment of hypothyroidism
GB201418172D0 (en) Use of cannabidiol in the treatment of intractable epilepsy
GB2549277B (en) Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
IL252819A0 (en) Hypochlorous acid preparations and methods for treating skin diseases
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
IL257908A (en) Methods for the treatment of epilepsy
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
PL3215157T3 (pl) Apilimod do stosowania w leczeniu czerniaka
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
GB201513543D0 (en) Compositions for use in the treatment of diabetes